Gene References


OASL (2’-5’-oligoadenylate synthetase-like)

Ren S, Yu H, Zhang H et al. Polymorphisms of interferon-inducible genes OAS associated with interferon-α treatment response in chronic HBV infection. Antiviral Res 2011; 89:232-7.

Su X, Yee LJ, Im K et al. Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C. J Hepatol 2008; 49:184-91.

Yakub I, Lillibridge KM, Moran A et al. Single nucleotide polymorphisms in genes for 2’-5’-oligoadenylate synthetase and RNase L inpatients hospitalized with West Nile virus infection. J Infect Dis 2005; 192:1741-8.

OPRM1 (opioid receptor, mu 1)

Anton RF, Oroszi G, O’Malley S et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 2008; 65:135-44.

Bart G, Heilig M, LaForge KS et al. Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Mol Psychiatry 2004; 9:547-9.

Bart G, Kreek MJ, Ott J et al. Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology 2005; 30:417-22.

Dlugos AM, Hamidovic A, Hodgkinson C et al. OPRM1 gene variants modulate amphetamine-induced euphoria in humans. Genes Brain Behav 2011; 10:199-209.

Drakenberg K, Nikoshkov A, Horváth MC et al. Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers. Proc Natl Acad Sci USA 2006; 103:7883-8.

Garriock HA, Tanowitz M, Kraft JB et al. Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. Am J Psychiatry 2010; 167:565-73.

Ginosar Y, Davidson EM, Meroz Y, Blotnick S, Shacham M, Caraco Y. Mu-opioid receptor (A118G) single-nucleotide polymorphism affects alfentanil requirements for extracorporeal shock wave lithotripsy: a pharmacokinetic-pharmacodynamic study. Br J Anaesth 2009; 103:420-7.

Glatt SJ, Bousman C, Wang RS et al. Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis. Drug Alcohol Depend 2007; 90:159-65.

Haile CN, Kosten TA, Kosten TR. Pharmacogenetic treatments for drug addiction: alcohol and opiates. Am J Drug Alcohol Abuse 2008; 34:355-81.

Hernandez-Avila CA, Wand G, Luo X, Gelernter J, Kranzler HR. Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet B Neuropsychiatr Genet 2003; 118:60-5.

Höllt V. A polymorphism (A118G) in the mu-opioid receptor gene affects the response to morphine-6-glucuronide in humans. Pharmacogenetics 2002; 12:1-2.

Ide S, Kobayashi H, Ujike H et al. Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms. Pharmacogenomics J 2006; 6:179-88.

Johnson AD, Zhang Y, Papp AC et al. Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues. Pharmacogenet Genomics 2008; 18:781-91.

Kim SG, Kim CM, Choi SW et al. A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology 2009; 201:611-8.

Landau R, Kern C, Columb MO, Smiley RM, Blouin JL. Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women. Pain 2008; 139:5-14.

Lerman C, Wileyto EP, Patterson F et al. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J 2004; 4:184-92.

Lötsch J, Skarke C, Grösch S, Darimont J, Schmidt H, Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 2002; 12:3-9.

Oertel BG, Schmidt R, Schneider A, Geisslinger G, Lotsch J. The mu-opioid receptor gene polymorphism 118A-G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenetics Genomics 2006; 16:625-636.

Oslin DW, Berrettini W, Kranzler HR et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003; 28:1546-52.

Ray LA, Hutchison KE. A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res 2004; 28:1789-95.

Reyes-Gibby CC, Shete S, Rakvåg T et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 2007; 130:25-30.

Romberg RR, Olofsen E, Bijl H et al. Polymorphism of mu-opioid receptor gene (OPRM1:c. 118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology 2005; 102:522-30.

Serý O, Prikryl R, Castulík L, St’astný F. A118G polymorphism of OPRM1 gene is associated with schizophrenia. J Mol Neurosci 2010; 41:219-22.

Shabalina SA, Zaykin DV, Gris P et al. Expansion of the human mu-opioid receptor gene architecture: novel functional variants. Hum Mol Genet 2009; 18:1037-51.

Wand GS, McCaul M, Yang X et al. The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 2002; 26:106-14.

Wong CA, McCarthy RJ, Blouin J, Landau R. Observational study of the effect of mu-opioid receptor genetic polymorphism on intrathecal opioid labor analgesia and post-cesarean delivery analgesia. Int J Obstet Anesth 2010; 19:246-53.

Wu D, Kang YS, Bickel U, Pardridge WM. Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine. Drug Metab Dispos 1997; 25:768-71.

Zhang W, Chang YZ, Kan QC et al. Association of human micro-opioid receptor gene polymorphism A118G with fentanyl analgesia consumption in Chinese gynaecological patients. Anaesthesia 2010; 65:130-5.

ORM1 (orosomucoid 1)

Colombo S, Buclin T, Décosterd LA et al. Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. Clin Pharmacol Ther 2006; 80:307-18.

Krynetskiy E, McDonnell P. Building individualized medicine: prevention of adverse reactions to warfarin therapy. J Pharmacol Exp Ther 2007; 322:427-34.

Tokita K, Schmid K. Variants of Alpha-1-acid glycoprotein. Nature 1963; 200:266.

Tomei L, Eap CB, Baumann P, Dente L. Use of transgenic mice for the characterization of human alpha 1-acid glycoprotein (orosomucoid) variants. Hum Genet 1989; 84:89-91.

Wadelius M, Chen LY, Eriksson N et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007; 121:23-34.

Yuasa I, Umetsu K, Vogt U et al. Human orosomucoid polymorphism: molecular basis of the three common ORM1 alleles, ORM1*F1, ORM1*F2, and ORM1*S. Hum Genet 1997, 99:393-8.

 A B C D E F G H I K L M N O P R S T U V W X Z